Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBP) Receivables (2016 - 2025)

Historic Receivables for Regen BioPharma (RGBP) over the last 12 years, with Q4 2025 value amounting to $232298.0.

  • Regen BioPharma's Receivables rose 8994.42% to $232298.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $232298.0, marking a year-over-year increase of 8994.42%. This contributed to the annual value of $204873.0 for FY2025, which is 11594.45% up from last year.
  • As of Q4 2025, Regen BioPharma's Receivables stood at $232298.0, which was up 8994.42% from $204873.0 recorded in Q3 2025.
  • In the past 5 years, Regen BioPharma's Receivables registered a high of $295466.0 during Q2 2022, and its lowest value of $12298.0 during Q4 2023.
  • For the 5-year period, Regen BioPharma's Receivables averaged around $156991.9, with its median value being $158042.0 (2021).
  • Its Receivables has fluctuated over the past 5 years, first plummeted by 9066.2% in 2023, then skyrocketed by 89445.44% in 2024.
  • Quarter analysis of 5 years shows Regen BioPharma's Receivables stood at $240617.0 in 2021, then plummeted by 45.27% to $131698.0 in 2022, then plummeted by 90.66% to $12298.0 in 2023, then soared by 894.45% to $122298.0 in 2024, then soared by 89.94% to $232298.0 in 2025.
  • Its Receivables stands at $232298.0 for Q4 2025, versus $204873.0 for Q3 2025 and $177147.0 for Q2 2025.